Impact of VEGF and VEGF receptor 1 (FLT1) expression on the prognosis of stage III esophageal cancer patients after radiochemotherapy

Strahlentherapie und Onkologie

Volumn 184, Issue 8, 2008, Pages 416-420

  Rades, Dirk ^a,b   Golke, Helmut ^a   Schild, Steven E ^c   Kilic, Ergin ^a,d  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c MAYO CLINIC   (United States)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Erythropoietin; Esophageal cancer; FLT1 expression; VEGF expression

Indexed keywords

CISPLATIN; ERYPO 10000; ERYTHROPOIETIN; FLUOROURACIL; IRON; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; ANTINEOPLASTIC AGENT; FLT1 PROTEIN, HUMAN; VASCULOTROPIN A;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CONTINUOUS INFUSION; CORRELATION ANALYSIS; DRUG UTILIZATION; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; ESOPHAGUS TUMOR; HEMOGLOBIN DETERMINATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; ERYTHROPOIETIN; ESOPHAGEAL NEOPLASMS; FEMALE; HEMOGLOBINOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 56149127251     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-008-1850-2     Document Type: Article

References (20)

1. Blohmer JU, Wurschmidt F, Petry U, et al. 6th interim analysis of a prospective, randomized, open and controlled AGO- and NOGGO-Intergroup study: sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for patients with high-risk cervical cancer. Proc Am Soc Clin Oncol 2003;22:447.abstract.
2. Chung GG, Yoon HH, Zerkowski MP, et al. Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer 2006;106:1677-84.
3. Decaussin M, Sartelet H, Robert C, et al. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol 1999;188:369-77.
4. Fenton C, Patel A, Dinauer C, et al. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid 2000;10:349-57.
5. Glaser CM, Millesi W, Kornek GV, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001;50:705-15.
6. Goldberg P. Study finds more deaths on Aranesp arm in cancer anemia study, no benefit seen [Newsletter]. Cancer Lett 2007;33:1.
7. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.
8. Kato H, Yoshikawa M, Miyazaki T, et al. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma. Anticancer Res 2002;22(6C):3977-84.
9. Klautke G, Fietkau R. Significance of radiation therapy for adenocarcinomas of the esophagus, gastroesophageal junction and gastric cancer with special reference to the MAGIC trial. Strahlenther Onkol 2007;183:163-9.
10. Kodaira T, Fuwa N, Itoh Y, et al. Multivariate analysis of treatment outcome in patients with esophageal carcinoma treated with definitive radiotherapy. Am J Clin Oncol 2003;26:392-7.
11. Patoney P, Naszaly A, Mayer A. Simultaneous radiochemotherapy and endoluminal HDR brachytherapy in esophageal cancer. Strahlenther Onkol 2007;183:94-8.
12. Polee MB, Hop WCJ, Kok TC, et al. Prognostic factors for survival in patients with advanced esophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer 2003;89:2045-50.
13. Rades D, Schulte R, Yekebas EF, et al. Radio(chemo)therapy plus resection versus radio(chemo)therapy alone for the treatment of stage III esophageal cancer. Strahlenther Onkol 2007;183:10-6.
14. Rades D, Tribius S, Yekebas EF, et al. Epoetin alfa improves survival after chemoradiation for stage III esophageal cancer: final results of a prospective observational study. Int J Radiat Oncol Biol Phys 2006;65:459-65.
15. Secord AA, Darcy KM, Hutson A, et al. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2007;106:221-32.
16. Shih CH, Ozawa S, Ando N, et al. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 2000;6:1161-8.
17. Tanigaki Y, Nagashima Y, Kitamura Y, et al. The expression of vascular enfothelial growth factor-A and -C, and receptors 1 and 3: correlation with lymph node metastasis and prognosis in tongue squamous cell carcinoma. Int J Mol Med 2004;14:389-95.
18. Vaupel P, Mayer A, Höckel. Impact of hemoglobin levels on tumor oxygenation: the higher, the better? Strahlenther Onkol 2006;182:63-71.
19. Vaupel P, Thews O, Mayer A, et al. Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level? Strahlenther Onkol 2002;178:727-31.
20. Zhukova LG, Zhukov NV, Lichinitser MR. Expression of Flt-1 and Flk-1 receptors for vascular endothelial growth factor on tumor cells as a new prognostic criterion for locally advanced breast cancer. Bull Exp Biol Med 2003;135:478-81.